Is Axonal Degeneration a Key Early Event in Parkinson's Disease?

Journal of Parkinson's Disease

Volumn 6, Issue 4, 2016, Pages 703-707

  Kurowska, Zuzanna ^a,b   Kordower, Jeffrey H ^c,d   Stoessl, A Jon ^e   Burke, Robert E ^f   Brundin, Patrik ^d   Yue, Zhenyu ^g   Brady, Scott T ^h,k   Milbrandt, Jeffrey ⁱ   Trapp, Bruce D ^a,b   Sherer, Todd B ^j   Medicetty, Satish ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Renovo Neural   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f Department of Medicine   (United States)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j THE MICHAEL J FOX FOUNDATION FOR PARKINSON'S RESEARCH   (United States)

^k MARINE BIOLOGICAL LABORATORY   (United States)

more..

Author keywords

animal disease models; autophagy; axonal transport; axons; dopaminergic neurons; Parkinson disease; retrograde degeneration; review; substantia nigra pars compacta; synapses

Indexed keywords

ALPHA SYNUCLEIN;

ARTICLE; AUTOPHAGY; DOPAMINERGIC NERVE CELL; DRUG TARGETING; HUMAN; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; ANIMAL; AXON; ORGANIZATION; PATHOLOGY;

ANIMALS; AXONS; CONGRESSES AS TOPIC; DOPAMINERGIC NEURONS; HUMANS; PARKINSON DISEASE;

EID: 84994113011     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-160881     Document Type: Article

References (30)

1. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, Halliday GM, &Bartus RT (2013) Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 136, 2419-2431.
2. Bartus RT, Herzog CD, Chu Y, Wilson A, Brown L, Siffert J, Johnson EM, Olanow CW, Mufson EJ, &Kordower JH (2011) Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains. Mov Disord, 26, 27-36.
3. Kirik D, Rosenblad C, &Björklund A (2000) Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci, 12, 3871-3882.
4. Sossi V, de la Fuente-Fernández R, Holden JE, Schulzer M, Ruth TJ, &Stoessl J (2004) Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: Their relation to diseasecompensatory mechanisms. J Cereb Blood Flow Metab, 24, 869-876.
5. Sossi V, de la Fuente-Fernández R, Nandhagopal R, Schulzer M, McKenzie J, Ruth TJ, Aasly JO, Farrer MJ, Wszolek ZK, &Stoessl JA (2010) Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord, 25, 2717-2723.
6. de la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, Mak E, McKenzie J, McCormick S, Sossi V, Ruth TJ, Lee CS, Calne DB, &Stoessl AJ (2011) Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol, 69, 803-810.
7. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, &Stoessl AJ (2000) In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol, 47, 493-503.
8. Fearnley JM, &Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain, 114(Pt 5), 2283-2301.
9. Tagliaferro P,& Burke RE (2016) Retrograde axonal degeneration in Parkinson disease. J Parkinsons Dis, 6, 1-15.
10. Chung CY, Koprich JB, Siddiqi H, &Isacson O (2009) Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alphasynucleinopathy. J Neurosci, 29, 3365-3373.
11. Decressac M, Mattsson B, Lundblad M, Weikop P, &Björklund A (2012) Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of --synuclein in midbrain dopamine neurons. Neurobiol Dis, 45, 939-953.
12. Tagliaferro P, Kareva T, Oo TF, Yarygina O, Kholodilov N, &Burke RE (2015) An early axonopathy in a hLRRK2(R1441G) transgenic model of Parkinson disease. Neurobiol Dis, 82, 359-371.
13. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, BogdanovM, Przedborski S, BealMF, Burke RE, &Li C (2009) Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci, 12, 826-828.
14. Kadkhodaei B, Alvarsson A, Schintu N, Ramsköld D, Volakakis N, Joodmardi E, Yoshitake T, Kehr J, Decressac M, Björklund A, Sandberg R, Svenningsson P, &Perlmann T (2013) Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl Acad Sci U S A, 110, 2360-2365.
15. Nordström U, Beauvais G, Ghosh A, Pulikkaparambil Sasidharan BC, Lundblad M, Fuchs J, Joshi RL, Lipton JW, Roholt A, Medicetty S, Feinstein TN, Steiner JA, Escobar Galvis ML, Prochiantz A, &Brundin P (2015) Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol Dis, 73, 70-82.
16. Sonnier L, Le Pen G, Hartmann A, Bizot J-C, Trovero F, Krebs M-O, &Prochiantz A (2007) Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1. J Neurosci, 27, 1063-1071.
17. Laguna A, Schintu N, Nobre A, Alvarsson A, Volakakis N, Jacobsen JK, Gómez-Galán M, Sopova E, Joodmardi E, Yoshitake T, Deng Q, Kehr J, Ericson J, Svenningsson P, Shupliakov O, &Perlmann T (2015) Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease. Nat Neurosci, 18, 826-835.
18. Galvin JE, Uryu K, Lee VM, &Trojanowski JQ (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A, 96, 13450-13455.
19. Duda JE, Giasson BI, Mabon ME, Lee VM-Y, &Trojanowski JQ (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol, 52, 205-210.
20. Kurowska Z, Kidd G, Benson E, Brundin P, Medicetty S, &Trapp B (2015) 3D-EM characterization of "axonal swellings" in the Engrailed-1 heterozygous mouse model of Parkinson's disease. In Movement Disorders Suppl. 1 (poster), San Diego, p. 1:94.
21. Rekaik H, Blaudin de Thé F-X, Fuchs J, Massiani-Beaudoin O, Prochiantz A, &Joshi RL (2015) Engrailed homeoprotein protects mesencephalic dopaminergic neurons from oxidative stress. Cell Rep, 13, 242-250.
22. Alvarez-Fischer D, Fuchs J, Castagner F, Stettler O, Massiani-Beaudoin O, Moya KL, Bouillot C, Oertel WH, Lombes A, FaigleW, Joshi RL, Hartmann A, &Prochiantz A (2011) Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci, 14, 1260-1266.
23. Stettler O, Joshi RL, Wizenmann A, Reingruber J, Holcman D, Bouillot C, Castagner F, Prochiantz A,& MoyaKL (2012) Engrailed homeoprotein recruits the adenosine A1 receptor to potentiate ephrin A5 function in retinal growth cones. Development, 139, 215-224.
24. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinás RR, &Brady ST (2007) 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci U S A, 104, 2442-2447.
25. Serulle Y, Morfini G, Pigino G, Moreira JE, Sugimori M, Brady ST, &Llinás RR (2007) 1-Methyl-4-phenylpyridinium induces synaptic dysfunction through a pathway involving caspase and PKCdelta enzymatic activities. Proc Natl Acad Sci U S A, 104, 2437-2441.
26. Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, &Kordower JH (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain, 135, 2058-2073.
27. Friedman LG, Lachenmayer ML, Wang J, He L, Poulose SM, Komatsu M, Holstein GR, &Yue Z (2012) Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of --synuclein and LRRK2 in the brain. J Neurosci, 32, 7585-7593.
28. Gerdts J, SummersDW, Milbrandt J,& DiAntonioA(2016) Axon self-destruction: New links among SARM1, MAPKs, and NAD+ metabolism. Neuron, 89, 449-460.
29. Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, &Milbrandt J (2015) SARM1 activation triggers axon degeneration locally via NAD+ destruction. Science, 348, 453-457.
30. Trapp BD, &Nave K-A (2008) Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci, 31, 247-269.